I forget the exact requirements, but the share pri
Post# of 1040
Not sure if there's a valuation requirement, but if there is, I could see that holding them back potentially. They already have sales of around 500K+ each quarter, and many biotechs uplist without having any revenues at all. If it can be done, I'm guessing that management has at least considered the prospects of uplisting.